LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Public ClinicalTrials.gov record NCT01685060. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib
Study identification
- NCT ID
- NCT01685060
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Interventions
- LDK378 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 25, 2012
- Primary completion
- Mar 28, 2016
- Completion
- Mar 28, 2016
- Last update posted
- Jun 18, 2017
2012 – 2016
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group Dept of Highlands Oncology Grp | Fayetteville | Arkansas | 72703 | — |
| City of Hope National Medical Center Dept of Oncology 2 | Duarte | California | 91010-3000 | — |
| University of California at Los Angeles Reg-5 | Los Angeles | California | 90095 | — |
| University of California at San Diego, Moores Cancer Ctr SC | San Diego | California | 92103 | — |
| Stanford University Medical Center Stanford Cancer Center(2) | Stanford | California | 94304 | — |
| University of Colorado Hospital SC | Aurora | Colorado | 80045 | — |
| Emory University School of Medicine/Winship Cancer Institute Dept of Oncology | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center SC | Chicago | Illinois | 60637 | — |
| University of Kansas Cancer Center DeptofUofKansas CancerCenter-2 | Kansas City | Kansas | 66160 | — |
| Cancer Center of Kansas Dept of CCK | Wichita | Kansas | 67214-3728 | — |
| Maryland Oncology Hematology, P.A. SC | Rockville | Maryland | 20850 | — |
| Massachusetts General Hospital Mass General | Boston | Massachusetts | 02114 | — |
| Levine Cancer Institute SC 1 | Charlotte | North Carolina | 28203 | — |
| Sarah Cannon Research Institute Drug Ship - 4 | Nashville | Tennessee | 37203 | — |
| U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office | Dallas | Texas | 75390 | — |
| Seattle Cancer Care Alliance SC-1 | Seattle | Washington | 98105 | — |
| University of Wisconsin Univ Wisc 2 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01685060, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01685060 live on ClinicalTrials.gov.